Abstract library

15 results for "Jung".
#499 Effect of Everolimus on Pharmacokinetics of Octreotide LAR in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis
Introduction: In RADIANT-2 (NCT00412061), Everolimus (E) plus Octreotide LAR (O) exhibited a clinically meaningful 5.1-month improvement in progression-free survival (PFS) v. placebo plus octreotide LAR (P+O) in patients (pts) with advanced neuroendocrine tumors (NET) and a history of carcinoid syndrome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Marianne E Pavel
#688 Does Small Mean Benign? Not for the WHO 2010 Classification of Gastrointestinal Neuroendocrine Tumors (NETs): A Case Report of a Small Rectal Neuroendocrine Neoplasm (NEN) with Distant Metastatic Spread
Introduction: The gastrointestinal tract is the most common site of primary NETs, just over a quarter of which are rectal. According to the WHO 2000/2004 non-functioning NETs, ≤2cm with no muscularis propria or vascular invasion are classified as well differentiated (WD) NET with benign behavior. However, several case series report metastatic spread from NETs in this category. In 2010, a new WHO classification was introduced with the premise that all NETs were considered malignant with metastatic potential.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Dr Tu Vinh Luong
#738 Interferon Alpha in the Management of Metastatic Neuroendocrine Tumors: A Retrospective Study in 37 Patients
Introduction: Interferon alpha (IFNα) has not been popular due to perceived lack of efficacy and toxicity profile. Current molecular targeted therapies demonstrate only modest anti-tumor effect with not insignificant toxicity.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: PROF Martyn Caplin
Keywords: Interferon
#758 Cardiac Metastases in Neuroendocrine Tumors- Diagnosis, Management and Outcomes
Introduction: Common areas of metastases in neuroendocrine tumors (NET) include liver, lymph nodes and bone. Limited data are available for cardiac metastases (CM).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: DR Vincent Cheung
#761 Use of Molecular Imaging to Differentiate Neuroendocrine Tumors from Other Synchronous Primary Cancers: A Case Series
Introduction: Approximately 22% of neuroendocrine tumors (NET) co-exist with other cancers.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: DR Vincent Cheung
Keywords: NET, synchronous, PET, Gallium, FDG
#768 Long-Term Haematological and Renal Toxicity of 90Yttrium-DOTA-Octreotate in the Treatment of Advanced Neuroendocrine Tumors(NETs)
Introduction: Peptide receptor radiation therapy (PRRT) is an established treatment for advanced NETs. Renal/haematological toxicity are recognised adverse effects.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: DR VINCENT Cheung
#856 DAXX and ATRX Loss Defines Chromosomal Instability and Poor Outcome in Pancreatic NET
Introduction: Chromosomal Instability (CIN) has been reported in pancreatic neuroendocrine tumors (pNETs) with poor outcome. However, no specific genetic background has been associated with CIN. Whole exome sequencing revealed mutations in DAXX (Death domain associated protein gene) and ATRX (ATR-X gene) in 40% of pNETs. DAXX and ATRX mutations in pNETs are associated with Alternative Lengthening of Telomeres (ALT) activation.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: PhD Ilaria Marinoni
Keywords: pNET, Daxx, Atrx, ALT, CIN
#909 Association between Dose of Octreotide and Tumor Control in Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) represent a heterogeneous group of tumors. Octreotide is used in the symptom control of NETs. The PROMID study demonstrated a benefit of octreotide on disease stabilization in midgut NETs, but a survival analysis was not possible due to insufficient events.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Sally C M Lau
Authors: Lau S C M, Cheung W, ...
Keywords: GI, NET, octreotide
#941 Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas
Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Christos Toumpanakis
#1350 Understanding a Neuroendocrine Tumors’ Impact on Health Systems: A Population-Based Economic Analysis of Patterns of Costs
Introduction: Little is known on resource utilization and health care costs in NET care.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Hallet Julie
Authors: Hallet J, Law C, Cheung M, Fischer H, ...
Keywords: costs, care patterns